The analyst suggests BioNTech could get a boost from increased vaccine demand. He argues that the severe flu season might incentivize people to get both flu and COVID vaccines, leading to potentially high Q4 sales for the company, especially since COVID infections have recently risen.
“so that's why I'm thinking the uh you know the sales fourth quarter sales for bioin Tech as well as moderna could be especially High hair bio intake is down 28 percent this uh so far this year moderna is down 25 percent so both of these stocks you know could get that boost from the covid vaccine.”